{
    "root": "dcbbbe17-09f4-4545-b123-7e506f708568",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Ticagrelor"
    },
    "value": "20250507",
    "ingredients": [
        {
            "name": "TICAGRELOR",
            "code": "GLH0314RVC"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "ticagrelor tablet p2y 12 platelet inhibitor indicated • reduce risk cardiovascular ( cv ) death , myocardial infarction ( myocardial infarction ) , stroke patients acute coronary syndrome ( acs ) history myocardial infarction . least first 12 months following acs , superior clopidogrel . ticagrelor tablets also reduces risk stent thrombosis patients stented treatment acs . ( 1.1 ) • reduce risk first myocardial infarction stroke patients coronary artery disease ( cad ) high risk events . limited setting , efficacy ticagrelor tablet established population type 2 diabetes mellitus ( t2dm ) . ( 1.2 ) • reduce risk stroke patients acute ischemic stroke ( nih stroke scale score ≤5 ) high-risk transient ischemic attack ( tia ) . ( 1.3 )",
    "contraindications": "• acs history myocardial infarction initiate treatment 180 mg oral loading dose ticagrelor tablets . administer 90 mg twice daily first year . one year , administer 60 mg twice daily . ( 2.2 ) • patients cad prior stroke myocardial infarction administer 60 mg ticagrelor tablets twice daily . ( 2.3 ) • acute ischemic stroke initiate treatment 180 mg loading dose ticagrelor tablets continue 90 mg twice daily 30 days . ( 2.4 ) ticagrelor tablets daily maintenance dose aspirin 75 100 mg. ( 2 ) however , patients undergone pci , consider single antiplatelet therapy ticagrelor tablets based evolving risk thrombotic versus bleeding events . ( 2.2 )",
    "warningsAndPrecautions": "ticagrelor tablet 90 mg supplied yellow , round , biconvex , film-coated tablets debossed ‘ 522 ’ one side ‘ l ’ side . bottle 30 tablets child resistant closure , ndc 62332-241-30 bottle 60 tablets child resistant closure , ndc 62332-241-60 bottle 100 tablets child resistant closure , ndc 62332-241-31 bottle 1000 tablets , ndc 62332-241-91 storage handling store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "history intracranial hemorrhage . ( 4.1 ) active pathological bleeding . ( 4.2 ) hypersensitivity ticagrelor component product . ( 4.3 )",
    "indications_original": "Ticagrelor tablet is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablet was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3)",
    "contraindications_original": "• ACS or History of MI o Initiate treatment with 180 mg oral loading dose of ticagrelor tablets. Then administer 90 mg twice daily during the first year. After one year, administer 60 mg twice daily. (2.2) • Patients with CAD and No Prior Stroke or MI o Administer 60 mg ticagrelor tablets twice daily. (2.3) • Acute Ischemic Stroke o Initiate treatment with a 180 mg loading dose of ticagrelor tablets then continue with 90 mg twice daily for up to 30 days. (2.4) Use ticagrelor tablets with a daily maintenance dose of aspirin of 75 to 100 mg. (2) However, in patients who have undergone PCI, consider single antiplatelet therapy with ticagrelor tablets based on the evolving risk for thrombotic versus bleeding events. (2.2)",
    "warningsAndPrecautions_original": "Ticagrelor tablet 90 mg is supplied as a yellow, round, biconvex, film-coated tablets debossed with ‘522’ on one side and ‘L’ on other side. \n                  Bottle of 30 tablets with child resistant closure,   NDC 62332-241-30\n                  Bottle of 60 tablets with child resistant closure,   NDC 62332-241-60\n                  Bottle of 100 tablets with child resistant closure, NDC 62332-241-31\n                  Bottle of 1000 tablets, NDC 62332-241-91\n                    \n                  \n                     Storage and Handling \n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "History of intracranial hemorrhage. (4.1) Active pathological bleeding. (4.2) Hypersensitivity to ticagrelor or any component of the product. (4.3)"
}